Ozempic is entering health insurance.

Millions of Americans' health could be improved by a new generation of weight-loss medications, 

but the cost of these medications will provide a hurdle for the country's health care system. 

These medications are in extremely high demand. In order to avoid a shortage due to strong demand, 

Novo Nordisk announced last week that it would temporarily stop advertising Wegovy, 

a diabetes drug that was approved for weight loss in 2021. 

Despite not being licensed for weight loss, its sister medication with the same active component, Ozempic, 

is in considerable demand for off-label uses. And the market is only anticipated to expand: Eli Lilly has requested the FDA to approve Mounjaro, 

a different diabetes medication, for use in weight loss.

Top 7 facts about private signs zodiac